That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

WHAT TO KNOW The antiviral drug Paxlovid dramatically reduces the chance of death and hospitalization for people at high risk of severe COVID-19, but uptake is low, studies have found. Experts say ...

The third-quarter results encouraged Pfizer to bump up its annual revenue expectations for Comirnaty and Paxlovid to $10.5 billion, from its previous forecast of $8.5 billion.

People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.

Pfizer rides Paxlovid sales growth to better-than-expected third quarter FILE - The Pfizer logo is displayed at the company’s headquarters, Friday, Feb. 5, 2021, in New York.

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a U.S. national stockpile delivery led to $2.7 billion in sales for the drug, Pfizer said Tuesday.